Publications by authors named "M I Arranz"
Osteosarcoma is a rare disease, but it is the most frequent malignant bone tumor. Primary treatment consists of preoperative MAP (methotrexate (MTX), doxorubicin and cisplatin) chemotherapy followed by surgery and adjuvant chemotherapy. Pathological response to preoperative chemotherapy is one of the most important prognostic factors, but molecular biomarkers are lacking.
View Article and Find Full Text PDFVisits to hospital emergency departments by patients with multimorbidity, complex chronic conditions, and frailty are becoming an increasing challenge. A territorial strategy has been developed, based on automated preselection lists, a nurse case manager with specialized experience, and a multi-level territorial referral consensus. The feasibility of this approach has been demonstrated, with 368 alerts detected, 85% of which were well-selected.
View Article and Find Full Text PDFArticle Synopsis
- The study addresses the challenge of hand reanimation for patients with total paralysis by comparing two surgical techniques: functional free gracilis muscle transfer and biceps tendon transfer to finger flexors.
- Six patients were evaluated over an average follow-up of 7.5 years, with varying success rates based on the techniques used, as measured by the British Medical Research Council grading system.
- The study concludes that while tendon transfer may be less complex and still effective, functional free muscle transfer is preferable when possible due to its potential for better long-term muscular strength in finger flexion.
Article Synopsis
- The study investigates the genetic factors linked to severe COVID-19, specifically focusing on hospitalized cases in admixed Americans.
- Researchers conducted the largest genome-wide association study (GWAS) for COVID-19 hospitalization in this population, identifying four significant genetic associations, including two novel loci found in Latin Americans.
- The findings highlight the importance of including diverse populations in genomic research, aiming to improve understanding of genetic risks associated with COVID-19 across different ethnic groups.
Article Synopsis
- Standard first-line chemotherapy for small cell lung cancer (SCLC) combines platinum and etoposide, but while effective, it has limitations like non-durable responses and toxicity.
- Genetic variants in DNA-repair and etoposide metabolism genes were studied in 145 SCLC patients to predict treatment outcomes and safety, with findings linking certain genetic variants to better progression-free survival (PFS).
- The study shows potential markers, like the rs11615 variant, could help personalize treatment, especially in limited-stage SCLC, but more research is needed to confirm these results.